Hyperamylasemia among patients treated with omalizumab

E. Karabiber; O. O. Aktas; E. Ozdemir; E. Celebioglu; U. M. Sahiner; G. Karakaya; A. F. Kalyoncu

Hyperamylasemia among patients treated with omalizumab

E. Karabiber
, O. O. Aktas
, E. Ozdemir
, E. Celebioglu
, U. M. Sahiner
, G. Karakaya
, A. F. Kalyoncu

Div Allergy & Clin Immunol
Hacettepe University

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	323-324
Number of pages	2
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	72
Publication status	Published - Aug 2017
Event	Congress of the European-Academy-of-Allergy-and-Clinical-Immunology - Helsinki, Finland Duration: 17 Jun 2017 → 21 Jun 2017

Cite this

@article{246476d384ee4b15b5039f90e4701b0e,

title = "Hyperamylasemia among patients treated with omalizumab",

author = "E. Karabiber and Aktas, \{O. O.\} and E. Ozdemir and E. Celebioglu and Sahiner, \{U. M.\} and G. Karakaya and Kalyoncu, \{A. F.\}",

year = "2017",

month = aug,

language = "English",

volume = "72",

pages = "323--324",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

note = "Congress of the European-Academy-of-Allergy-and-Clinical-Immunology ; Conference date: 17-06-2017 Through 21-06-2017",

}

TY - JOUR

T1 - Hyperamylasemia among patients treated with omalizumab

AU - Karabiber, E.

AU - Aktas, O. O.

AU - Ozdemir, E.

AU - Celebioglu, E.

AU - Sahiner, U. M.

AU - Karakaya, G.

AU - Kalyoncu, A. F.

PY - 2017/8

Y1 - 2017/8

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000408773101336&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 0105-4538

VL - 72

SP - 323

EP - 324

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

T2 - Congress of the European-Academy-of-Allergy-and-Clinical-Immunology

Y2 - 17 June 2017 through 21 June 2017

ER -

Hyperamylasemia among patients treated with omalizumab

Other files and links

Cite this